Cookie Img
Send SMS    Call Me Free
Home » Products » Anti-Cancer Products » Cabazitaxel

Cabazitaxel

Cabazitaxel
Cabazitaxel
Product Code : #0100
Brand Name : Jevtana
Product Specifications
  • Formulations Type
  • Injectables
  • Formulations Form
  • Liquid
  • Gender/Age Group
  • Adult
Trade Information
  • Main Export Market(s)
  • Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
  • Main Domestic Market
  • All India
Product Description

Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid.[1] It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.[2][unreliable source?]

Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.


AMBICA PHARMA

Contact Us

( *represents compulsory fields )

Tips on getting accurate quotes. Please include product name, order quantity, usage, special requests if any in your inquiry.



AMBICA PHARMA All Rights Reserved.